Skip to content

Treatment of acetaminophen toxicity

Comparison of the adverse effects of intravenous N-acetylcysteine with intravenous and oral N-acetylcystein in acetaminophen toxicity

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201112146948N2
Enrollment
50
Registered
2011-12-26
Start date
2009-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acetaminphen toxicity. Poisoning by nonopioid analgesics, antipyretics and antirheumatics (Salicylate)s

Interventions

Intervention 1: The group A (only intravenous N-acetylcystein or NAC) was managed by IV NAC with 150mg/kg infused in 200cc of 5% dextrose water (5%DW) in 30 minutes, followed by a 4 hour infusion of 5
Treatment - Drugs
The group A (only intravenous N-acetylcystein or NAC) was managed by IV NAC with 150mg/kg infused in 200cc of 5% dextrose water (5%DW) in 30 minutes, followed by a 4 hour infusion of 50mg/kg of NAC in
In group B (oral and IV NAC), oral NAC was given by 140mg/kg in 200cc of 5%DW. If vomiting occurred in any patient during one hour after the ingestion of the oral NAC then 10mg metoclopramide was give

Sponsors

Isfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: The inclusion criteria: Patients with acetaminophen poisoning; ingesting the toxic acetaminophen dose (=7.5g); aged = 18 years old; coming to the hospital before 8 hours after acetaminophen ingestion. The exclusion criteria: Less than 7.5g acetaminophen ingesting; aged under 18 years old; coming to the hospital after 8 hours after acetaminophen ingestion; vomiting two times after oral NAC was given; pregnant patients; those who had risk factors for hepatic toxicity (e.g. those who had hepatic cirrhosis; chronic ethanol ingestion; usage of substances that induce cytochrome P450 enzyme activity including rifampin; phenobarbital; isoniazid; phenytoin and carbamazepine).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Anaphylactoid reactions. Timepoint: during NAC (N-acetylcysteine) infusion. Method of measurement: observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNastaran Eizadi Mood

Isfahan University of Medical Sciences

izadi@med.mui.ac.ir+98 31 1668 0011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026